Genetic diversity and natural selection of Plasmodium falciparum Pf41 vaccine candidate in clinical isolates from Senegal

Abstract The merozoite surface antigen Pf41 was previously identified among the top 10 of new malaria vaccine candidates. Pf41 possesses red blood cell binding regions and conserved domains. We used population genetics approaches to determine the genetic diversity and to identify regions under balan...

Full description

Saved in:
Bibliographic Details
Main Authors: Rokhaya Sané, Babacar Souleymane Sambe, Aissatou Diagne, Joseph Faye, Fatoumata Diene Sarr, Serigne Ousmane Mbacké Diaw, Ibrahima Sarr, Arona Sabène Diatta, Hélène Ataume Mawounge Diatta, Papa Mbacké Sembène, Inès Vigan-Womas, Aissatou Toure-Balde, Faith Osier, Makhtar Niang
Format: Article
Language:English
Published: Nature Portfolio 2025-05-01
Series:Scientific Reports
Subjects:
Online Access:https://doi.org/10.1038/s41598-025-00784-y
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850133341538353152
author Rokhaya Sané
Babacar Souleymane Sambe
Aissatou Diagne
Joseph Faye
Fatoumata Diene Sarr
Serigne Ousmane Mbacké Diaw
Ibrahima Sarr
Arona Sabène Diatta
Hélène Ataume Mawounge Diatta
Papa Mbacké Sembène
Inès Vigan-Womas
Aissatou Toure-Balde
Faith Osier
Makhtar Niang
author_facet Rokhaya Sané
Babacar Souleymane Sambe
Aissatou Diagne
Joseph Faye
Fatoumata Diene Sarr
Serigne Ousmane Mbacké Diaw
Ibrahima Sarr
Arona Sabène Diatta
Hélène Ataume Mawounge Diatta
Papa Mbacké Sembène
Inès Vigan-Womas
Aissatou Toure-Balde
Faith Osier
Makhtar Niang
author_sort Rokhaya Sané
collection DOAJ
description Abstract The merozoite surface antigen Pf41 was previously identified among the top 10 of new malaria vaccine candidates. Pf41 possesses red blood cell binding regions and conserved domains. We used population genetics approaches to determine the genetic diversity and to identify regions under balancing selection for the potential inclusion of Pf41 as candidate in a multicomponent vaccine. We screened 116 clinical isolates collected from different administrative regions in Senegal for P. falciparum positivity, Pf41 amplification and sequencing. We analyzed Pf41 sequences for polymorphism, natural selection, haplotype prevalence and linkage disequilibrium. Neutrality tests (Tajima’s D, FLD, FLF and MEME) were computed using DnaSP v6. and Datamonkey Hyphy. Population Analysis with Reticulate Trees (Popart) version 1.7 software was used to construct haplotypes network showing the distribution of haplotypes per study site. P. falciparum positivity from the 116 successfully tested samples was 93.1% of which 73 were successfully sequenced for Pf41. We found a low genetic diversity (π = 0.00144 ± 0.00022) and high haplotype diversity (Hd = 0.765 ± 0.037) of Pf41 sequences that can be attributed to linkage disequilibrium. We identified several substitutions under positive selection and negatively selected codons at inter-species level in the central and 6-Cys domains of Pf41, respectively. The predominant SNP S232R was found fixed by positive selection in Senegalese isolates. The genetic diversity of Pf41 antigen is low in clinical isolates from Senegal. With a central domain under balancing selection and two highly conserved 6-Cys domains under negative selection due to functional constraints, the Pf41 antigen appears as a good vaccine candidate. Further monitoring of allelic variants on larger and diverse sets of samples would justify the rational for functional assays and Pf41 integration in a multicomponent vaccine.
format Article
id doaj-art-5f69de0ae19d4e96b96375d6f3f35270
institution OA Journals
issn 2045-2322
language English
publishDate 2025-05-01
publisher Nature Portfolio
record_format Article
series Scientific Reports
spelling doaj-art-5f69de0ae19d4e96b96375d6f3f352702025-08-20T02:31:59ZengNature PortfolioScientific Reports2045-23222025-05-0115111010.1038/s41598-025-00784-yGenetic diversity and natural selection of Plasmodium falciparum Pf41 vaccine candidate in clinical isolates from SenegalRokhaya Sané0Babacar Souleymane Sambe1Aissatou Diagne2Joseph Faye3Fatoumata Diene Sarr4Serigne Ousmane Mbacké Diaw5Ibrahima Sarr6Arona Sabène Diatta7Hélène Ataume Mawounge Diatta8Papa Mbacké Sembène9Inès Vigan-Womas10Aissatou Toure-Balde11Faith Osier12Makhtar Niang13Pôle Immunophysiopathologie et Maladies Infectieuses, Institut Pasteur de DakarPôle Immunophysiopathologie et Maladies Infectieuses, Institut Pasteur de DakarPôle Immunophysiopathologie et Maladies Infectieuses, Institut Pasteur de DakarPôle Epidémiologie, Recherche Clinique et Sciences des Données, Institut Pasteur de DakarPôle Epidémiologie, Recherche Clinique et Sciences des Données, Institut Pasteur de DakarPôle Immunophysiopathologie et Maladies Infectieuses, Institut Pasteur de DakarPôle Immunophysiopathologie et Maladies Infectieuses, Institut Pasteur de DakarPôle Immunophysiopathologie et Maladies Infectieuses, Institut Pasteur de DakarPôle Immunophysiopathologie et Maladies Infectieuses, Institut Pasteur de DakarDépartement de Biologie Animale, Faculté des Sciences et Techniques, Université Cheikh Anta Diop de DakarPôle Immunophysiopathologie et Maladies Infectieuses, Institut Pasteur de DakarPôle Immunophysiopathologie et Maladies Infectieuses, Institut Pasteur de DakarCentre for Geographic Medicine Research (Coast), Kenya Medical Research Institute-Wellcome Trust Research ProgrammePôle Immunophysiopathologie et Maladies Infectieuses, Institut Pasteur de DakarAbstract The merozoite surface antigen Pf41 was previously identified among the top 10 of new malaria vaccine candidates. Pf41 possesses red blood cell binding regions and conserved domains. We used population genetics approaches to determine the genetic diversity and to identify regions under balancing selection for the potential inclusion of Pf41 as candidate in a multicomponent vaccine. We screened 116 clinical isolates collected from different administrative regions in Senegal for P. falciparum positivity, Pf41 amplification and sequencing. We analyzed Pf41 sequences for polymorphism, natural selection, haplotype prevalence and linkage disequilibrium. Neutrality tests (Tajima’s D, FLD, FLF and MEME) were computed using DnaSP v6. and Datamonkey Hyphy. Population Analysis with Reticulate Trees (Popart) version 1.7 software was used to construct haplotypes network showing the distribution of haplotypes per study site. P. falciparum positivity from the 116 successfully tested samples was 93.1% of which 73 were successfully sequenced for Pf41. We found a low genetic diversity (π = 0.00144 ± 0.00022) and high haplotype diversity (Hd = 0.765 ± 0.037) of Pf41 sequences that can be attributed to linkage disequilibrium. We identified several substitutions under positive selection and negatively selected codons at inter-species level in the central and 6-Cys domains of Pf41, respectively. The predominant SNP S232R was found fixed by positive selection in Senegalese isolates. The genetic diversity of Pf41 antigen is low in clinical isolates from Senegal. With a central domain under balancing selection and two highly conserved 6-Cys domains under negative selection due to functional constraints, the Pf41 antigen appears as a good vaccine candidate. Further monitoring of allelic variants on larger and diverse sets of samples would justify the rational for functional assays and Pf41 integration in a multicomponent vaccine.https://doi.org/10.1038/s41598-025-00784-yPlasmodium falciparumPf416-CysGenetic diversityNatural selectionVaccine candidate
spellingShingle Rokhaya Sané
Babacar Souleymane Sambe
Aissatou Diagne
Joseph Faye
Fatoumata Diene Sarr
Serigne Ousmane Mbacké Diaw
Ibrahima Sarr
Arona Sabène Diatta
Hélène Ataume Mawounge Diatta
Papa Mbacké Sembène
Inès Vigan-Womas
Aissatou Toure-Balde
Faith Osier
Makhtar Niang
Genetic diversity and natural selection of Plasmodium falciparum Pf41 vaccine candidate in clinical isolates from Senegal
Scientific Reports
Plasmodium falciparum
Pf41
6-Cys
Genetic diversity
Natural selection
Vaccine candidate
title Genetic diversity and natural selection of Plasmodium falciparum Pf41 vaccine candidate in clinical isolates from Senegal
title_full Genetic diversity and natural selection of Plasmodium falciparum Pf41 vaccine candidate in clinical isolates from Senegal
title_fullStr Genetic diversity and natural selection of Plasmodium falciparum Pf41 vaccine candidate in clinical isolates from Senegal
title_full_unstemmed Genetic diversity and natural selection of Plasmodium falciparum Pf41 vaccine candidate in clinical isolates from Senegal
title_short Genetic diversity and natural selection of Plasmodium falciparum Pf41 vaccine candidate in clinical isolates from Senegal
title_sort genetic diversity and natural selection of plasmodium falciparum pf41 vaccine candidate in clinical isolates from senegal
topic Plasmodium falciparum
Pf41
6-Cys
Genetic diversity
Natural selection
Vaccine candidate
url https://doi.org/10.1038/s41598-025-00784-y
work_keys_str_mv AT rokhayasane geneticdiversityandnaturalselectionofplasmodiumfalciparumpf41vaccinecandidateinclinicalisolatesfromsenegal
AT babacarsouleymanesambe geneticdiversityandnaturalselectionofplasmodiumfalciparumpf41vaccinecandidateinclinicalisolatesfromsenegal
AT aissatoudiagne geneticdiversityandnaturalselectionofplasmodiumfalciparumpf41vaccinecandidateinclinicalisolatesfromsenegal
AT josephfaye geneticdiversityandnaturalselectionofplasmodiumfalciparumpf41vaccinecandidateinclinicalisolatesfromsenegal
AT fatoumatadienesarr geneticdiversityandnaturalselectionofplasmodiumfalciparumpf41vaccinecandidateinclinicalisolatesfromsenegal
AT serigneousmanembackediaw geneticdiversityandnaturalselectionofplasmodiumfalciparumpf41vaccinecandidateinclinicalisolatesfromsenegal
AT ibrahimasarr geneticdiversityandnaturalselectionofplasmodiumfalciparumpf41vaccinecandidateinclinicalisolatesfromsenegal
AT aronasabenediatta geneticdiversityandnaturalselectionofplasmodiumfalciparumpf41vaccinecandidateinclinicalisolatesfromsenegal
AT heleneataumemawoungediatta geneticdiversityandnaturalselectionofplasmodiumfalciparumpf41vaccinecandidateinclinicalisolatesfromsenegal
AT papambackesembene geneticdiversityandnaturalselectionofplasmodiumfalciparumpf41vaccinecandidateinclinicalisolatesfromsenegal
AT inesviganwomas geneticdiversityandnaturalselectionofplasmodiumfalciparumpf41vaccinecandidateinclinicalisolatesfromsenegal
AT aissatoutourebalde geneticdiversityandnaturalselectionofplasmodiumfalciparumpf41vaccinecandidateinclinicalisolatesfromsenegal
AT faithosier geneticdiversityandnaturalselectionofplasmodiumfalciparumpf41vaccinecandidateinclinicalisolatesfromsenegal
AT makhtarniang geneticdiversityandnaturalselectionofplasmodiumfalciparumpf41vaccinecandidateinclinicalisolatesfromsenegal